Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cumberland Pharmaceuticals

3.22
-0.4900-13.21%
Post-market: 3.220.00000.00%19:52 EDT
Volume:143.57K
Turnover:489.98K
Market Cap:48.17M
PE:-14.03
High:3.76
Open:3.76
Low:3.12
Close:3.71
Loading ...

Kenneth Krogulski, Director, Reports Acquisition of Common Shares in Cumberland Pharmaceuticals Inc

Reuters
·
12 Jul

Cumberland Pharmaceuticals Unveils Promising Phase 2 Trial Results for Ifetroban in Treating Duchenne Muscular Dystrophy Heart Disease

Reuters
·
23 Jun

A.J. Kazimi, Chairman and CEO, Reports Acquisition of Common Shares in Cumberland Pharmaceuticals Inc

Reuters
·
06 Jun

Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

Reuters
·
28 May

Cumberland, Qureight Collaborate on Lung Disease Treatment Trial

MT Newswires Live
·
14 May

Cumberland Pharmaceuticals Partners With Qureight to Advance Innovative Idiopathic Pulmonary Fibrosis Treatment Research

THOMSON REUTERS
·
14 May

Cumberland Q1 Adj. EPS $0.16 Up From $(0.05) YoY, Sales $11.71M Up From $8.50M YoY

Benzinga
·
07 May

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

THOMSON REUTERS
·
07 May

Fight Dmd Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

THOMSON REUTERS
·
20 Mar

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

PR Newswire
·
20 Mar

Cumberland Pharmaceuticals Full Year 2024 Earnings: US$0.46 loss per share (vs US$0.44 loss in FY 2023)

Simply Wall St.
·
13 Mar

Cumberland Pharmaceuticals: Key Insights from Earnings Call

TIPRANKS
·
06 Mar

Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

GuruFocus.com
·
05 Mar

Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Advances

TIPRANKS
·
05 Mar

Cumberland: Q4 Earnings Snapshot

Associated Press Finance
·
05 Mar

Cumberland Q4 Adj EPS $(0.02) Up From $(0.11) YoY, Sales $10.44M Up From $9.35M YoY

Benzinga
·
05 Mar

Cumberland Pharmaceuticals Q4 Revenue USD 10.4 Million

THOMSON REUTERS
·
05 Mar

Cumberland options imply 26.1% move in share price post-earnings

TIPRANKS
·
05 Mar

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

PR Newswire
·
26 Feb